Prime Highlights
- LSL Pharma has acquired Juno OTC, expanding its footprint in Canada’s over-the-counter healthcare market.
- The acquisition adds strong retail partnerships and regulatory expertise to LSL Pharma’s growing portfolio.
Key Facts
- The acquisition of Juno OTC was valued at $5 million and was completed on December 23, 2025.
- LSL Pharma will take full operational control of Juno OTC from January 1, 2026.
Background:
LSL Pharma Group Inc. (TSXV: LSL), a Canadian integrated pharmaceutical company, has announced the successful completion of its acquisition of Juno OTC Inc., alongside the final closing of a $2 million non-brokered private placement, bringing total financing raised to $12 million.
The purchase price comprised $2.5 million in cash paid on Dec. 23, 2025, the issuance of 5,509,642 Class A common shares of LSL Pharma on the same date, and a deferred cash payment of $500,000 payable on Jan. 1, 2027. The deferred amount remains subject to customary working capital adjustments.
The acquisition was conducted at arm’s length and qualifies as an expedited acquisition under TSX Venture Exchange Policy 5.3. No finder’s fees were paid, and the transaction remains subject to final approval by the TSXV. All securities issued in connection with the acquisition are subject to a statutory hold period of four months and one day.
Alongside the acquisition, LSL Pharma closed a concurrent non-brokered private placement of unsecured convertible debentures, raising $2 million in gross proceeds. The debentures are convertible into common shares at a price of $0.45 per share. As part of the transaction, Juno Pharmaceuticals LP subscribed for $1.5 million of the debentures.
This closing follows the previously announced $10 million brokered private placement, bringing LSL Pharma’s total recent fundraising to $12 million.
Juno OTC is a leading supplier in Canada’s private label over-the-counter consumer healthcare market, serving major retailers with core healthcare products under established store brands. The company is known for strong regulatory and quality standards and has long-term ties with Canadian retailers. Juno OTC also holds all necessary Health Canada licenses to import and distribute OTC products.
LSL Pharma Group Inc. specializes in the development, manufacturing, and commercialization of sterile ophthalmic pharmaceuticals, as well as pharmaceutical, cosmetic, and natural health products across multiple dosage forms. Its portfolio includes Steri-Med Pharma Inc., LSL Laboratory Inc., Virage Santé Inc., Dermolab Pharma Ltd., and Du-Var Laboratory Inc.
The securities referenced in this announcement have not been registered under U.S. securities laws and may not be offered or sold in the United States absent registration or an applicable exemption.
